161948-70-5

Usage

Uses

Used in Pharmaceutical Synthesis:
Boc-Pip-OH is utilized as a key component in the synthesis of various pharmaceuticals, particularly those containing the piperidine ring structure. Its role in protecting amines during the synthesis process ensures the successful formation of desired compounds, contributing to the development of new and effective medications.
Used in Organic Synthesis:
In the realm of organic synthesis, Boc-Pip-OH serves as a versatile protecting group for amines. This function is critical in preventing unwanted side reactions, thereby facilitating the synthesis of complex organic compounds with greater precision and yield.
Used in Drug Discovery and Development:
Boc-Pip-OH is employed as a valuable tool in drug discovery and development processes. Its stability and ease of use in chemical reactions make it an ideal candidate for the synthesis of potential drug candidates, accelerating the pace of research and innovation in the pharmaceutical industry.
Used in Chemical Research:
In academic and industrial research settings, Boc-Pip-OH is leveraged for its unique properties in chemical reactions. Its application in the synthesis of novel compounds and the exploration of new reaction pathways furthers the understanding of organic chemistry and contributes to the advancement of scientific knowledge.

Upstream product

• 79-08-3 bromoacetic acid 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 146117-95-5 methyl 2-(piperidin-4-yloxy)acetate hydrochloride 
• 146117-95-5 methyl 4-piperidinyloxy-acetate hydrochloride 
• 146117-93-3 2-(piperidin-4-yloxy)acetic acid 
• 189889-45-0 4-(ethoxycarbonylmethoxy)piperidine-1-carboxylic acid tert-butylester 

Downstream Products

• 857653-96-4 tert-butyl 4-(2-amino-2-oxoethoxy)piperidine-1-carboxylate 
• 220386-75-4 ethyl 5-[N-(N-t-butoxycarbonyl-4-piperidyloxyacetyl)-L-4-nitrophenylalanyl]-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-2-acetate 
• 942212-12-6 C₂₉H₂₈N₄O₅S 
• 942212-08-0 C₂₆H₃₀N₄O₅S 
• 942212-07-9 C₂₇H₃₁N₅O₄ 
• 942212-06-8 C₂₈H₃₂N₄O₄ 
• 942212-14-8 C₂₈H₃₂N₄O₅ 
• 942212-10-4 C₃₀H₂₈N₄O₅ 
• 942212-09-1 C₂₉H₂₆N₄O₅ 
• 942212-13-7 C₂₆H₂₈N₄O₅ 
• 163210-40-0 tert-butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs

The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active i

JANUS KINASES INHIBITORS, COMPOSITIONS THEREOF AND USE THEREOF

Compounds of Formula (00A) and salts thereof, wherein R1, R2 R3, R4 and n are defined herein, are useful as inhibitors of one or more Janus kinases. Also provided are pharmaceutical compositions that include a compound of Formula (00A) and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient. ( 00A)

Prodrugs of Compounds that Enhance Antifungal Activity and Compositions of Said Prodrugs

The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active i

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

2-Arylbenzoxazoles as CETP inhibitors: Raising HDL-C in cynoCETP transgenic mice

We describe structure-activity studies leading to the discovery of 2-arylbenzoxazole 3, the first in a series to raise serum high-density lipoprotein cholesterol levels in transgenic mice. Replacement of the 4-piperidinyloxy moiety with piperazinyl provid

CETP INHIBITORS

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. I

GPCR AGONISTS

Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.

HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS

Compounds of Formula (I), R1-A-V-B-R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.

Compounds with growth hormone releasing properties

Compounds of peptide mimetic nature having the general formula I STR1 wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals

The structural requirements for N-terminal features for the minimal structure of growth hormone secretagogues derived from ipamorelin are investigated. It is found, that incorporation of nonpolar peptidomimetic amino acids at the N-terminal can replace the Aib-His moiety and lead to compounds with high in vitro potency with respect to their growth hormone secretagogue properties. New unnatural amino acids with double bonds, ether- linkages, and 1,3-phenylene-moieties in the backbone proved to be valuable dipeptidomimetics. Using them, growth hormone secretagogues with high potencies were obtained.